NRx Pharmaceuticals welcomed the Executive Order signed by President Trump on April 18, “Accelerating Medical Treatments for Serious Mental Illness,” which directs the FDA to expedite review of psychedelic medications and support their development for treating depression, PTSD, and suicidality. In the order, the President states that “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”
CNPV Program and Real-World Evidence
The order directs the Commissioner of the US Food and Drug Administration to provide Commissioner’s National Priority Vouchers (CNPV) to appropriate psychedelic drugs that have received a Breakthrough Therapy designation. NRx has applied for a CNPV in support of its upcoming New Drug Application for NRX-100. The Presidential order directs the Department of Health and Human Services and FDA to collaborate with the Department of Veterans Affairs to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, facilitating timely evaluation and approval of drugs that meet standards for approval. This is expected to facilitate NRx’s proposed use of Real World Evidence and already-completed federally-funded clinical trials in support of drug approval.
NRx Programs and Initiatives
NRx is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. The company filed an IND application to study the use of NRX-101 for enhancement of Transcranial Magnetic Stimulation (TMS). NRx also announced the incorporation of NRx Defense Systems, Inc., a Florida-based Research and Development subsidiary developing neuroplastic treatments combining D-cycloserine with TMS under robotic-enabled neuro-navigation. Combined neuroplastic therapy for depression and PTSD is an increasing area of focus within military organizations because of the recognized five-fold increased risk in front-line troops and first responders. The company anticipates unveiling the prototype robotic-enabled TMS technology with neuroplastic therapy at the 14th Annual meeting of the Clinical TMS Society from June 4-6.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/getnews-2026-4-21-presidential-executive-order-to-accelerate-approval-of-psychedelic-medications-those-being-developed-by-nrx-pharmaceuticals-inc-nasdaq-nrxp